TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04195243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin Pill
Description: The patient will take one pill, every 24 hr, during 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin Pill
Description: The patient will take one pill, every 24 hr, during 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: The patient will take one pill, every 24 hr, during 7 days
Study: NCT02504905

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: single TMS pulses at intensities in random order from 0 to 100% (increasing at 5% intervals) of stimulator output at a frequency of 0.1 Hz. Three pulses will be delivered at each intensity. MEPs will be recorded and their amplitudes will be plotted against the corresponding stimulation intensity. This curve will provide three significant parameters: (a) S50 intensity (intensity for which we get a MEP 50 % of its maximal size); (b) estimated resting motor threshold (RMT): the abscissa where the tangent to the slope crosses the x axis; and (c) the maximum MEP ( plateau value).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: single TMS pulses at intensities in random order from 0 to 100% (increasing at 5% intervals) of stimulator output at a frequency of 0.1 Hz. Three pulses will be delivered at each intensity. MEPs will be recorded and their amplitudes will be plotted against the corresponding stimulation intensity. This curve will provide three significant parameters: (a) S50 intensity (intensity for which we get a MEP 50 % of its maximal size); (b) estimated resting motor threshold (RMT): the abscissa where the tangent to the slope crosses the x axis; and (c) the maximum MEP ( plateau value).
Study: NCT02374268

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise program alone

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise program alone

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Combined exercise program and nutrition supplement
Study: NCT01273948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bavituximab
Description: 1. Bavituximab 3 mg/kg given by intravenous (IV) infusion once weekly, plus oral ribavirin 1000 mg (weight \<75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks or~2. Bavituximab 0.3 mg/kg given by IV infusion once weekly, plus oral ribavirin 1000 mg (weight \<75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks or

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bavituximab
Description: 1. Bavituximab 3 mg/kg given by intravenous (IV) infusion once weekly, plus oral ribavirin 1000 mg (weight \<75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks or~2. Bavituximab 0.3 mg/kg given by IV infusion once weekly, plus oral ribavirin 1000 mg (weight \<75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks or

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon (PEG-IFN)
Description: Pegylated interferon (PEG-IFN) alpha-2a 180 micrograms given by subcutaneous (SC) injection once weekly, plus oral ribavirin 1000 mg (weight \<75 kg) or 1200 mg (weight greater than or equal 75 kg) divided into twice-daily doses, for 12 weeks
Study: NCT00796302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate HCl
Description: For children weighing less than 25 kg, the dose will be titrated at 18 mg for the first 7 days, 36 mg for the next 4 days, and, if needed, 54 mg for the next 4 days. For children weighing more than 25 kg, the dose will be titrated at 18 mg for the first 4 days, 36 mg for the next 3 days, 54 mg for the next 4 days, and 72 mg for the next 3 days.~Once the child's optimal dose is established, he or she will continue on that dose for the rest of the 21-week trial.~One pill is taken once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate HCl
Description: For children weighing less than 25 kg, the dose will be titrated at 18 mg for the first 7 days, 36 mg for the next 4 days, and, if needed, 54 mg for the next 4 days. For children weighing more than 25 kg, the dose will be titrated at 18 mg for the first 4 days, 36 mg for the next 3 days, 54 mg for the next 4 days, and 72 mg for the next 3 days.~Once the child's optimal dose is established, he or she will continue on that dose for the rest of the 21-week trial.~One pill is taken once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: For children weighing less than 45 kg, the dose will start at 0.5 mg at night. After 4 days, the child's dose may be increased to 1 mg a day. On Day 8, the child's dose may be increased to 1.5 mg a day. On Day 16, the child's dose may be increased to 2.0 mg a day. On Day 22, the child's dose may be increased to 2.5 mg a day.~For children weighing more than 45 kg, the dose will start at 0.5 mg at night. After 4 days, the child's dose may be increased to 1.0 mg a day. On Day 8, the child's dose may be increased to 1.5 mg a day. On Day 12, the child's dose may be increased to 2.0 mg a day. On Day 15, the child's dose may be increased to 2.5 mg a day. On Day 18, the child's dose may be increased to 3 mg a day. On Day 23, the child's dose may be increased to 3.5 mg a day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Management Training (PMT)
Description: PMT will include individual parent sessions held weekly for 9 weeks, with two booster sessions to be completed during the 3-month extension. Sessions will include development of problem-solving skills and behavior management strategies, practice activities, and role-playing with the behavioral therapist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Management Training (PMT)
Description: PMT will include individual parent sessions held weekly for 9 weeks, with two booster sessions to be completed during the 3-month extension. Sessions will include development of problem-solving skills and behavior management strategies, practice activities, and role-playing with the behavioral therapist.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: One pill will be taken once daily for the first 4 days and then twice daily until Week 21.
Study: NCT01832948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Study: NCT03859635

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Bupivacaine
Description: 20 ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Bupivacaine
Description: 20 ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine, 0.25%
Description: 10 ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine, 0.25%
Description: 10 ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine, 0.5%
Description: 30 ml
Study: NCT02374268

Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist control group
Study: NCT02652481

Intervention type: DEVICE
Group type: OTHER
Intervention: ImageReady MR Conditional Defibrillation System
Description: ImageReady MR Conditional Defibrillation System Components:~Device Name Device Model Number Pulse Generators Phase I and II Phase II Only \* CRT-D (IS1/DF4/IS4) VR ICD (DF4) DR ( dual chamber) ICD (IS1/DF4) ORIGEN™ MINI ICD ORIGEN EL ICD ORIGEN X4 CRT INOGEN™ MINI ICD INOGEN EL ICD INOGEN X4 CRT DYNAGEN™ MINI ICD DYNAGEN EL ICD DYNAGEN X4 CRT-D AUTOGEN ™ MINI ICD\* AUTOGEN EL ICD\* AUTOGEN X4 CRT-D\* Right Atrial Leads and Accessories FINELINE™ II Sterox FINELINE II Sterox EZ Suture Sleeves for FINELINE II Leads INGEVITY™ MRI\* Suture Sleeve for INGEVITY MRI\* IS-1 Lead Port Plug 7145 Right Ventricular Leads and Accessories RELIANCE 4-FRONT™ (DF4)\* Suture Sleeve for RELIANCE 4-FRONT leads\*; ENDOTAK RELIANCE™ (DF4) Left Ventricular Leads and Accessories ACUITY™ X4 (IS4) Suture Sleeve for ACUITY X4 leads~\* May only be used internationally outside the US
Study: NCT01803308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB9200
Description: Part A open-label, single ascending doses of SB9200 from 100mg - 1500mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB9200
Description: Part B randomised 6:2 (active:placebo) using recommended Part B starting dose, and ascending to up to 1500mg for 7-14 days of dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Part B randomised 6:2 (active:placebo) using anhydrous lactose capsules identical to active comparator, minus active ingredient.
Study: NCT00474695

Intervention type: DRUG
Intervention: Lucentis
Description: 0.05 mg intravitreal injection
Study: NCT01624675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Subjects weighing less than 20 kilogram (kg) received risperidone 0.25 milligram per day (mg/day) up to Day 4. On Day 4, dose was titrated in increments of 0.25 mg/day (up to a daily dose of 1.0 mg) at the regular study visit thereafter till Week 8. Subjects weighing greater than or equal to (\>=) 20 kg received risperidone 0.5 mg/day up to Day 4. On Day 4, dose was titrated in increments of 0.5 mg per day (up to a daily dose of 2.5 mg) at the regular visit thereafter till Week 8. The maximum daily dose for subjects weighing \>= 45 kg was 3.0 mg. For subjects weighing \>=45 kg, the maximum daily dose was 3.0 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo matching with risperidone orally up to 8 weeks.
Study: NCT04407390

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside
Description: The patients will receive 1 g of nicotinamide riboside or placebo orally every morning for 14 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03311373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen A
Description: 2 inhalations BGF MDI; no spacer device; no oral charcoal - reference formulation/total systemic exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen A
Description: 2 inhalations BGF MDI; no spacer device; no oral charcoal - reference formulation/total systemic exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen A
Description: 2 inhalations BGF MDI; no spacer device; no oral charcoal - reference formulation/total systemic exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen A
Description: 2 inhalations BGF MDI; no spacer device; no oral charcoal - reference formulation/total systemic exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen B
Description: 2 inhalations BGF MDI; AeroChamber Plus Flow-Vu spacer device; no oral charcoal - test formulation/total systemic exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen B
Description: 2 inhalations BGF MDI; AeroChamber Plus Flow-Vu spacer device; no oral charcoal - test formulation/total systemic exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen B
Description: 2 inhalations BGF MDI; AeroChamber Plus Flow-Vu spacer device; no oral charcoal - test formulation/total systemic exposure
Study: NCT03358069

Intervention type: DIAGNOSTIC_TEST
Intervention: Emergence agitation scale
Description: Emergence agitation scale: PAED scale \> 10 defined as positive for Emergence agitation (EA) Post hospitalize behavioral questionnaire (PHBQ) positive Post operative behavioral changes defines as 10 % change from sum score of PHBQ
Study: NCT03311373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen B
Description: 2 inhalations BGF MDI; AeroChamber Plus Flow-Vu spacer device; no oral charcoal - test formulation/total systemic exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen C
Description: 2 inhalations BGF MDI; no spacer device; with oral charcoal - reference formulation/lung exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen C
Description: 2 inhalations BGF MDI; no spacer device; with oral charcoal - reference formulation/lung exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen C
Description: 2 inhalations BGF MDI; no spacer device; with oral charcoal - reference formulation/lung exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen C
Description: 2 inhalations BGF MDI; no spacer device; with oral charcoal - reference formulation/lung exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen D
Description: 2 inhalations BGF MDI; AeroChamber Plus Flow-Vu spacer device; with oral charcoal - test formulation/lung exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen D
Description: 2 inhalations BGF MDI; AeroChamber Plus Flow-Vu spacer device; with oral charcoal - test formulation/lung exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen D
Description: 2 inhalations BGF MDI; AeroChamber Plus Flow-Vu spacer device; with oral charcoal - test formulation/lung exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen D
Description: 2 inhalations BGF MDI; AeroChamber Plus Flow-Vu spacer device; with oral charcoal - test formulation/lung exposure
Study: NCT02943057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% guttae ganciclovir
Description: 2% guttae ganciclovir 5 times a day for 6 weeks
Study: NCT00979836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Dobesilate
Description: 500 mg/ three times/day for 6 months (capsules)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Dobesilate
Description: 500 mg/ three times/day for 6 months (capsules)
Study: NCT03565081

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PWS elastic band training group
Description: PWS participants received 9 sets exercises for the major muscle groups, over 24 weeks, three times a week, for a total of 72 sessions.
Study: NCT02330133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Women's Reproductive Health
Description: Targeted text and video information on website for women aged 25-55 to avoid unplanned pregnancy and sexually transmitted infections

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online sexual health content
Description: Online general text-based information about reproductive health issues and strategies for preventing sexually transmitted infections
Study: NCT04454658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-744
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-744
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-744
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-744
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-744
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Tablet; Oral
Study: NCT02855931

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Middle turbinate resection
Study: NCT02149251

Intervention type: GENETIC
Intervention: Pre-genetic diagnosis
Study: NCT03234205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: MRI standard protocol with addition of:~* a second clinical respiratory belt besides belt usually installed for clinical examination~* a second clinical electrocardiogram sensor besides sensor usually installed for clinical examination~* 12 sequences during free respiration are added lasting supplementary 15 minutes~* Use of cardiac antennae usually used for cardiac MRI scans
Study: NCT02657031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prochlorperazine
Description: prochlorperazine 10 mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine 0.3 mg/kg IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: Diphenhydromine 25 mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron 4 mg IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline 500 cc IV Bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: Normal Saline 500 cc IV Bolus
Study: NCT02624362

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Suggestion
Description: suggestions about potential beneficial effects of the odor are given

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthmogenic Suggestion
Description: suggestions about potential negative effects of the odor are given
Study: NCT01653197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Curiosity
Description: The recipient will be prompted to scratch off for answer to question.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Curiosity linked to Action
Description: The recipient will be prompted to scratch off for answer only after he/she makes an appointment.
Study: NCT02624362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phenylethyl Alcohol odor
Description: Over the course of 15 minutes, participants, receive 15 short sniffs of Phenylethyl Alcohol odor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phenylethyl Alcohol odor
Description: Over the course of 15 minutes, participants, receive 15 short sniffs of Phenylethyl Alcohol odor
Study: NCT01239030

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate Hydrochloride Extended Release Capsules
Description: Biphentin Methylphenidate ER Once-A-Day Capsules
Study: NCT00555009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genotropin
Description: Subcutaneous injection, starting dose 0.2mg/day for males and 0.3mg/day for female with dose titration at 0.1mg to 0.2 mg increments in accordance to IGF-1 results for a total duration of 36 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection, with dummy dose titration for a total duration of 36 weeks.
Study: NCT04472975

Intervention type: DRUG
Intervention: Exposure to one or more disease-modifying drug(s)(DMDs) used to treat MS
Description: Individuals with MS exposed to one or more DMDs (beta-interferon, glatiramer acetate, natalizumab, fingolimod, dimethyl fumarate, teriflunomide, alemtuzumab, daclizumab or ocrelizumab; regardless of dose, frequency or duration of treatment) between 1st January 1996 and 31st March 2018 in five Canadian provinces.
Study: NCT02717975

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Use of catheter valve before 'trial removal of catheter'
Description: The investigators are comparing two groups of patients (Group A) Trial removal of urinary catheter in patients with urinary retention after applying catheter valve and closing it 3-4 hours before catheter removal.
Study: NCT03358069

Intervention type: DIAGNOSTIC_TEST
Intervention: Emergence agitation scale
Description: Emergence agitation scale: PAED scale \> 10 defined as positive for Emergence agitation (EA) Post hospitalize behavioral questionnaire (PHBQ) positive Post operative behavioral changes defines as 10 % change from sum score of PHBQ

Intervention type: DIAGNOSTIC_TEST
Intervention: Emergence agitation scale
Description: Emergence agitation scale: PAED scale \> 10 defined as positive for Emergence agitation (EA) Post hospitalize behavioral questionnaire (PHBQ) positive Post operative behavioral changes defines as 10 % change from sum score of PHBQ

Intervention type: DIAGNOSTIC_TEST
Intervention: Emergence agitation scale
Description: Emergence agitation scale: PAED scale \> 10 defined as positive for Emergence agitation (EA) Post hospitalize behavioral questionnaire (PHBQ) positive Post operative behavioral changes defines as 10 % change from sum score of PHBQ
Study: NCT02717975

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trial removal of catheter in patients with urinary retention
Description: The investigators are comparing two groups of patients (Group B) Trial removal of urinary catheter in patients with urinary retention without using catheter valve - 'Traditional method'
Study: NCT03443869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir
Description: LET 480mg (or 240 mg when administered concomitantly with cyclosporin A) once daily for 28 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir
Description: 900 mg VGCV tablet orally, once daily for 28 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir (ACV)
Description: 400 mg over-encapsulated ACV tablet orally, every 12 hours for 28 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to ACV
Description: Over-encapsulated placebo tablet orally, every 12 hours for 28 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to LET
Description: Placebo to LET tablet orally, once daily for 28 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to VGCV
Description: Placebo to VGCV tablet orally, once daily for 28 weeks
Study: NCT04052399

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: anodal transcranial direct current stimulation
Description: Anodal tDCS of the lateral hypothalamus-cognitive or medial hypothalamus-cognitive network.~The total injected current will never go beyond 4 milliamp, which will be split among the different stimulation electrodes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cathodal transcranial direct current stimulation
Description: Cathodal tDCS of the lateral hypothalamus-cognitive or medial hypothalamus-cognitive network.~The total injected current will never go beyond 4 milliamp, which will be split among the different stimulation electrodes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Single blind sham stimulation (ramp-up ramp-down stimulation will be applied for 30 seconds)
Study: NCT00301106

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adenovirus-mediated human interleukin-12
Description: The purified ADV-hIL12 is suspended in formulation buffer (10mM Tris, pH 7.5/~1mM MgCl2/ 150mM NaCl/ 10% glycerol) and aliquoted into 1ml cryovials. The filled vials are stored at or below -60 degC.
Study: NCT03322462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18
Description: 370 megabecquerel (MBq) IV single-dose

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain PET Scan
Description: positron emission tomography (PET) scan of the brain